FLGT
Fulgent Genetics presents FID-007 Phase 2 data at ASCO 2026 meeting
Fulgent presented updated data for FID-007 in combination with cetuximab for recurrent/metastatic head and neck cancer, showing 61.9% objective response rate and manageable safety profile as of April 16, 2026. The company plans to advance to Phase 3 studies, which could expand its therapeutic pipeli…
FLGT
Fulgent Genetics presents FID-007 Phase 2 data at ASCO 2026 meeting
Fulgent announced interim data from its Phase 2 study of FID-007 combined with cetuximab for recurrent/metastatic head and neck cancer, showing 60% objective response rate and favorable safety profile. The presentation at ASCO 2026 could validate the therapeutic potential of the company's oncology p…
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.